125 related articles for article (PubMed ID: 34795021)
1. Stratified follow-up for endometrial cancer: a move to more personalized cancer care.
Sarwar A; Van Griethuysen J; Waterhouse J; Dehbi HM; Eminowicz G; McCormack M
Int J Gynecol Cancer; 2021 Dec; 31(12):1564-1571. PubMed ID: 34795021
[TBL] [Abstract][Full Text] [Related]
2. Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits.
Coleridge S; Morrison J
Int J Gynecol Cancer; 2020 Aug; 30(8):1177-1182. PubMed ID: 32376734
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
4. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
5. Stage 1C grade 3 endometrial cancer: the KK Hospital gynaecological oncology group experience.
Siow TR; Yeo MC; Khoo-Tan HS; Yap SP; Soong YL; Chua EJ; Soh LT; Lim YK; Chia YN; Yam KL
Int J Gynecol Cancer; 2010 Dec; 20(9):1557-62. PubMed ID: 21119369
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of risk factors for recurrence after treatment of endometrial uterine cancer].
Zalewski K; Rzepka J; Madry R; Dańska-Bidzińska A; Bidzinski M
Ginekol Pol; 2009 Sep; 80(9):687-93. PubMed ID: 19886243
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and patterns of recurrence in lymphovascular space invasion positive women with stage IIIC endometriod endometrial cancer.
Cuylan ZF; Oz M; Ozkan NT; Comert GK; Sahin H; Turan T; Akbayir O; Kuscu E; Celik H; Dede M; Gungor T; Meydanli MM; Ayhan A
J Obstet Gynaecol Res; 2018 Jun; 44(6):1140-1149. PubMed ID: 29516573
[TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
[TBL] [Abstract][Full Text] [Related]
11. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
[TBL] [Abstract][Full Text] [Related]
12. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
13. The nature of early-stage endometrial cancer recurrence-A national cohort study.
Jeppesen MM; Jensen PT; Gilså Hansen D; Iachina M; Mogensen O
Eur J Cancer; 2016 Dec; 69():51-60. PubMed ID: 27816832
[TBL] [Abstract][Full Text] [Related]
14. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.
AlHilli MM; Mariani A; Bakkum-Gamez JN; Dowdy SC; Weaver AL; Peethambaram PP; Keeney GL; Cliby WA; Podratz KC
Gynecol Oncol; 2014 Jun; 133(3):485-93. PubMed ID: 24690476
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI?
Ureyen I; Karalok A; Turkmen O; Kimyon G; Akdas YR; Akyol A; Tasci T; Turan T
Arch Gynecol Obstet; 2020 Mar; 301(3):737-744. PubMed ID: 31883046
[TBL] [Abstract][Full Text] [Related]
17. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.
Chattopadhyay S; Cross P; Nayar A; Galaal K; Naik R
Int J Gynecol Cancer; 2013 May; 23(4):690-7. PubMed ID: 23518862
[TBL] [Abstract][Full Text] [Related]
18. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
19. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
